Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Tandem Meetings 2023 | Retrospective analysis of PTCy-based GvHD prophylaxis in elderly alloSCT recipients

Rajneesh Nath • 20 Feb 2023
Tandem Meetings 2023
General Cyclophosphamide
BMT CTN 1703

Rajneesh Nath, MD, Banner MD Anderson Cancer Center, Gilbert, AZ, outlines the rationale and results of a single-center retrospective study evaluating the safety and efficacy of post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GvHD) prophylaxis in patients older than 70 years old who received allogeneic stem cell transplantation (alloSCT) with reduced-intensity conditioning (RIC). The study showed high rates of GvHD relapse-free survival (RFS) and overall survival (OS) at one and three years, demonstrating that PTCy is effective and well tolerated in elderly patients. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Actinium – Consultant; Incyte – Advisory board

More from Rajneesh Nath

4:04
LBA: Phase III study of Iomab-B prior to allogeneic transplantation vs conventional care in R/R AML
Rajneesh Nath • 20 Feb 2023

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals